

Journal of Investigative Dermatology – Accepted manuscript

<https://doi.org/10.1016/j.jid.2017.05.017>

## The Syk tyrosine kinase is required for skin inflammation in an in vivo mouse model of epidermolysis bullosa acquisita

Tamás Németh<sup>1,2,5</sup>, Oana Virtic<sup>3,5</sup>, Cassian Sitaru<sup>3,4</sup>, and Attila Mócsai<sup>1,2</sup>

<sup>1</sup>Department of Physiology, Semmelweis University School of Medicine, 1094 Budapest, Hungary; <sup>2</sup>MTA-SE “Lendület” Inflammation Physiology Research Group of the Hungarian Academy of Sciences and Semmelweis University, 1094 Budapest, Hungary; <sup>3</sup>Department of Dermatology, University Hospital Freiburg, 79104 Freiburg, Germany; <sup>4</sup>BIOS Centre for Biological Signalling Studies, 79104 Freiburg, Germany

<sup>5</sup>These authors contributed equally to this work.

Corresponding author:

Attila Mócsai, MD, PhD

Department of Physiology

Semmelweis University School of Medicine

Tuzolto utca 37-47, 1094 Budapest, Hungary

Tel: +36-1-459-1500 x60-409

Fax: +36-1-266-7480

E-mail: [mocsai.attila@med.semmelweis-univ.hu](mailto:mocsai.attila@med.semmelweis-univ.hu)

## **ABSTRACT**

The inflammatory form of epidermolysis bullosa acquisita is caused by autoantibodies against type VII collagen (C7), a component of the dermal-epidermal junction. We have previously shown that myeloid Src-family kinases mediate skin inflammation triggered by anti-C7 antibodies. Here we identify the Syk tyrosine kinase as a critical component of autoantibody-induced skin inflammation downstream of Src-family kinases. Immobilized C7–anti-C7 immune complexes triggered neutrophil activation and Syk phosphorylation in a Src-family kinase-dependent manner. Bone marrow chimeric mice lacking Syk in their hematopoietic compartment were completely protected from skin inflammation triggered by anti-C7 antibodies despite normal circulating anti-C7 levels. Syk deficiency abrogated the accumulation of CXCL2, IL-1 $\beta$  and LTB<sub>4</sub> at the site of inflammation and resulted in defective in vivo neutrophil recruitment. Syk<sup>-/-</sup> neutrophils had a normal intrinsic migratory capacity but failed to release CXCL2 or LTB<sub>4</sub> upon activation by immobilized C7–anti-C7 immune complexes, indicating a role for Syk in the amplification of the inflammation process. These results identify Syk as a critical component of skin inflammation in a mouse model of epidermolysis bullosa acquisita and as a potential therapeutic target in epidermolysis bullosa acquisita and other mechanistically related inflammatory skin diseases such as bullous pemphigoid.

## INTRODUCTION

Typical examples of subepidermal blistering skin diseases are bullous pemphigoid and epidermolysis bullosa acquisita, the latter disease having both an inflammatory and a non-inflammatory (mechanobullous) form (Ludwig and Zillikens, 2011; Kim and Kim, 2013). Both bullous pemphigoid and epidermolysis bullosa acquisita are caused by autoimmune targeting of components of the dermal-epidermal junction and are triggered by autoantibodies against the hemidesmosomal proteins BP230/BP180 or the dermal anchoring fibril protein type VII collagen, respectively (Schmidt and Zillikens, 2013; Baum et al., 2014; Turcan and Jonkman, 2015). In case of bullous pemphigoid and the inflammatory form of epidermolysis bullosa acquisita, this leads to local inflammation and disruption of the dermal-epidermal junction, mediated by complement activation and leukocyte (mainly eosinophil and neutrophil) infiltration (Schmidt and Zillikens, 2013). In contrast, autoantibodies appear to directly decrease the adhesive function of the basement membrane without initiating significant inflammation in the non-inflammatory form of epidermolysis bullosa acquisita (Kim and Kim, 2013). Unfortunately, further details of the pathomechanism of bullous pemphigoid and epidermolysis bullosa are poorly understood and, therefore, the therapeutic options are rather limited (Kasperkiewicz and Schmidt, 2009).

A number of in vivo models mimic bullous pemphigoid or the inflammatory form of epidermolysis bullosa acquisita by utilizing active or passive immunization against components of the dermal-epidermal junction in experimental animals (Iwata et al., 2015). The most widely used model relies on the passive immunization of mice with IgG antibodies against the immunodominant NC1 domain of type VII collagen (Sitaru et al., 2005; Sitaru, 2007; Ludwig, 2012). Since this intervention triggers substantial inflammation and inflammatory pathway components are critical to disease pathogenesis (see below), this model is believed to mimic the inflammatory but not the non-inflammatory form of epidermolysis bullosa acquisita.

Animal models of bullous pemphigoid and epidermolysis bullosa acquisita have revealed striking similarities between the pathomechanism of the two disease models. Critical components include activating Fc-receptors (Sitaru et al., 2005; Zhao et al., 2006; Kasperkiewicz et al., 2012; Schulze et al., 2014), the alternative pathway of complement activation (Liu et al., 1995; Sitaru et al., 2005; Mihai et al., 2007) as well as myeloid cells such as neutrophils (Liu et al., 1997; Chiriac et al., 2007). Our recent signaling studies revealed complete protection of mice lacking three Src-family kinases expressed in myeloid cells (Hck, Fgr and Lyn) from skin inflammation triggered by antibodies against type VII collagen (Kovács et al., 2014), while mice lacking PI3K $\beta$  (Kulkarni et al., 2011) or the CARD9 adapter protein (Németh et al., 2016) were

partially protected. Additional experiments pointed to a critical role for those molecules within the neutrophil compartment in all three cases.

Syk is a nonreceptor tyrosine kinase primarily expressed in cells of hematopoietic origin (Mócsai et al., 2010). Syk is involved in signal transduction of a number of tyrosine kinase-coupled receptors including  $\beta_2$ -integrins and various Fc-receptors (Mócsai et al., 2002; Mócsai et al., 2003; Mócsai et al., 2010; Németh et al., 2016). Src-family kinases are involved in Syk activation in most of those cases (Mócsai et al., 2002; Mócsai et al., 2006; Mócsai et al., 2010; Kovács et al., 2014). Hematopoietic or neutrophil-specific deletion of Syk protects mice from arthritis development in the K/B $\times$ N serum-transfer model (Jakus et al., 2010; Elliott et al., 2011) and Syk has been proposed to be a potential target in rheumatoid arthritis and other autoimmune inflammatory diseases (Mócsai et al., 2010; Weinblatt et al., 2010; Geahlen, 2014). However, the role of Syk in autoimmune inflammatory skin diseases is still entirely unclear.

The above findings and the lack of information on the role of Syk in autoimmune dermatitis prompted us to test the role of Syk in an *in vivo* model of the inflammatory form of epidermolysis bullosa acquisita in experimental mice. Our results indicate that Syk is critically involved in skin inflammation triggered by autoantibodies against type VII collagen, identifying Syk as a potential therapeutic target in epidermolysis bullosa acquisita and, possibly, other inflammatory skin diseases of similar pathomechanism.

## RESULTS

### *Neutrophil activation by type VII collagen-containing immune complexes*

We have previously shown that immobilized human serum albumin (HSA)–anti-HSA immune complexes trigger robust activation of neutrophils (Jakus et al., 2008). To determine whether immune complexes containing dermo-epidermal junctional proteins can also activate neutrophils, we generated immobilized immune complexes using a His-tagged fragment of the immunodominant NC1 domain of murine type VII collagen (His-C7) and rabbit polyclonal IgG (anti-C7) against the GST-fusion protein of the same fragment (Sitaru et al., 2002; Csorba et al., 2010). Plating wild-type mouse neutrophils on such immobilized immune complexes triggered robust activation of the cells as measured by the release of superoxide anions (Fig 1a;  $p = 4 \times 10^{-6}$ ). Neutrophil activation required both the antigen and the antibody components (Fig 1a). His-C7–anti-C7 immune complexes also triggered spreading of the cells over the immune complex-coated surface (Fig 1b).

To test the antigen specificity of neutrophil activation, ELISA plates were coated with His-C7 or HSA, blocked and then incubated with anti-C7 or anti-HSA antibodies.

As shown in Fig 1c, neutrophils mounted a robust respiratory burst in the presence of matching antigen-antibody pairs (His-C7 with anti-C7 or HSA with anti-HSA;  $p = 8 \times 10^{-6}$  and  $p = 1.9 \times 10^{-3}$ , respectively) but not when non-matching antigen-antibody pairs were used.

Taken together, type VII collagen-containing immune complexes are able to specifically activate neutrophil functions.

### *Src-family kinases mediate neutrophil respiratory burst and Syk activation by type VII collagen-containing immune complexes*

We have recently shown that the Src-family kinases Hck, Fgr and Lyn are critically involved in neutrophil activation triggered by HSA–anti-HSA immune complexes (Kovács et al., 2014). To test whether this also applies to type VII collagen-containing immune complexes, we tested the responses of Hck<sup>-/-</sup>Fgr<sup>-/-</sup>Lyn<sup>-/-</sup> (3x SFK KO) neutrophils. As shown in Fig 1d, 3x SFK KO neutrophils failed to release superoxide under such conditions.

Syk is a non-receptor tyrosine kinase activated downstream of Src-family kinases in several immunoreceptor-induced signaling pathways (Mócsai et al., 2010; Futosi et al., 2013). We next tested whether this is also true for neutrophil activation by type VII collagen-containing immune complexes. Wild-type neutrophils plated on immobilized His-C7–anti-C7 immune complexes showed Syk phosphorylation (a measure of Syk activation) whereas no such response could be observed in 3x SFK KO neutrophils (Fig 1e; see also the entire blots in Fig S1).

Taken together, neutrophil activation by type VII collagen-containing immune complexes triggers Syk activation downstream of the Src-family kinases Hck, Fgr and Lyn.

### *Generation and characterization of Syk<sup>-/-</sup> bone marrow chimeras*

The above findings raised the possibility that Syk may also be involved in anti-C7 antibody-induced skin inflammation. Unfortunately, the perinatal lethality of genetically Syk-deficient (Syk<sup>-/-</sup>) animals (Turner et al., 1995; Abtahian et al., 2003; Mócsai et al., 2010) did not allow us to test this in intact animals. To overcome that problem, we generated bone marrow chimeras lacking Syk only in their hematopoietic compartment (termed Syk<sup>-/-</sup> bone marrow chimeras) by transplanting fetal liver cells of Syk<sup>-/-</sup> fetuses into lethally irradiated wild-type recipients (Mócsai et al., 2002). Control chimeras (termed wild-type bone marrow chimeras) were generated by parallel transplantation of Syk<sup>+/+</sup> or Syk<sup>+/-</sup> fetal liver cells. Differential expression of CD45 alleles

in the donor (CD45.2) and the recipient (CD45.1) cells allowed identification of donor- and recipient-derived cells. As shown in Fig 2a, practically all peripheral blood neutrophils of wild-type or *Syk*<sup>-/-</sup> bone marrow chimeras expressed the donor-derived CD45.2 allele, indicating complete repopulation of the hematopoietic compartment by donor-derived cells. In addition, Syk was present in lysates of freshly isolated neutrophils and platelets, as well as of bone marrow-derived macrophages and mast cells, from wild-type but not *Syk*<sup>-/-</sup> bone marrow chimeras (Fig 2b). Therefore, we were able to replace the wild-type hematopoietic compartment of the recipient mice with donor-derived (e. g. *Syk*<sup>-/-</sup>) cells.

We did not observe any difference in circulating neutrophils numbers between wild-type and *Syk*<sup>-/-</sup> bone marrow chimeras (Fig 2c;  $p = 0.69$ ), and similar numbers of bone marrow neutrophils could be isolated from chimeras of the two genotypes (Fig 2d;  $p = 0.37$ ). In addition, *Syk*<sup>-/-</sup> neutrophils expressed normal levels of the neutrophil maturation marker Ly6G, the  $\beta_2$  integrin component CD18, the major neutrophil chemokine receptor CXCR2, as well as the Fc-receptors Fc $\gamma$ RII/III and Fc $\gamma$ RIV (Fig 2e). Therefore, the *Syk*<sup>-/-</sup> mutation did not interfere with the generation or maturation of neutrophils, or the expression of critical cell surface receptors.

#### *Syk*<sup>-/-</sup> bone marrow chimeras are completely protected from skin inflammation triggered by anti-C7 antibodies

We next subjected wild-type and *Syk*<sup>-/-</sup> bone marrow chimeras to repeated subcutaneous injection of anti-C7 or normal rabbit IgG/PBS, as a model of inflammatory autoimmune blistering skin diseases (Sitaru et al., 2005). Our previous studies have indicated a critical role for the Fc portion of the pathogenic antibodies in this model (Sitaru et al., 2005). As shown in Fig 3a, wild-type chimeras treated with anti-C7 antibodies developed significant signs of skin inflammation at several body areas, ranging from loss of the superficial layer of the skin (most prominent in the buccal/periorbital area) to severe inflammation and scarring at the most severely affected places (most prominent on the ears). Importantly, *Syk*<sup>-/-</sup> bone marrow chimeras were completely protected from development of all those skin inflammatory changes (Fig 3a).

Quantification of the overall skin changes revealed that the percentage of the affected body surface area gradually increased over the assay period in wild-type chimeras, whereas no signs of the disease could be observed in *Syk*<sup>-/-</sup> chimeras (Fig 3b;  $p = 0.022$ ). Similarly, the overall clinical score also gradually increased during the assay period in wild-type chimeras without any signs of the disease in *Syk*<sup>-/-</sup> chimeras (Fig 3c;  $p = 6.0 \times 10^{-3}$ ).

A possible explanation for the above findings could be that the  $SyK^{-/-}$  mutation affects the metabolism of the injected pathogenic antibodies. However, no differences in circulating anti-C7 antibody titers could be observed between the wild-type and  $SyK^{-/-}$  genotypes (Fig 3d;  $p = 0.69$ ).

We next tested skin inflammation by histological analysis of the ear tissue. As shown in Fig 3e, anti-C7 antibody treatment triggered substantial thickening of the ear of wild-type chimeras with prominent leukocyte infiltration. However, no such inflammatory changes could be observed in  $SyK^{-/-}$  bone marrow chimeras.

Taken together the  $SyK^{-/-}$  mutation blocks the capability of anti-C7 antibodies to trigger skin inflammation both at the macroscopic and microscopic levels, without affecting their removal from the circulation.

### *The $SyK^{-/-}$ mutation blocks neutrophil recruitment without affecting the intrinsic migratory capacity of neutrophils*

The inflammatory form of epidermolysis bullosa acquisita is characterized by a significant influx of granulocytes (eosinophils and neutrophils) which are likely involved in the inflammation process (Schmidt and Zillikens, 2013). As shown in Fig 4a, anti-C7 antibodies triggered dramatic influx of neutrophils to the ear of wild-type bone marrow chimeras, which appears to be a peculiarity of this mouse model (as compared to the dominant infiltration by eosinophils in the inflammatory form of human epidermolysis bullosa acquisita). Importantly, and in agreement with the histological pictures (Fig 3e), no such accumulation of neutrophils could be observed in  $SyK^{-/-}$  chimeras (Fig 4a;  $p = 7.7 \times 10^{-3}$ ).

The simplest explanation for the above findings would be an intrinsic migration defect of  $SyK^{-/-}$  neutrophils. However, we previously reported normal migration of  $SyK^{-/-}$  neutrophils towards various proinflammatory agonists both under in vitro and in vivo conditions (Mócsai et al., 2002; Mócsai et al., 2003). To test this question in anti-C7-induced skin inflammation, we generated mixed bone marrow chimeras carrying leukocytes (including neutrophils) from both CD45.1-expressing wild type and CD45.2-expressing wild type or  $SyK^{-/-}$  bone marrow cells. Such chimeras developed signs of inflammation due to the presence of wild type cells. Comparative flow cytometric analysis of CD45.1/2 expression in the inflammatory infiltrate and the peripheral blood then allowed us to compare the migration of wild type and  $SyK^{-/-}$  neutrophils within the same animal. The percentage values for the peripheral blood and ear samples are presented in Fig 4b, whereas the relative migratory capacity of the CD45.2 (wild type or  $SyK^{-/-}$ ) cells relative to the CD45.1 (wild type) reference cells (calculated based on the data in Fig 4b) is shown in Fig 4c. As expected, the percentage of wild type CD45.2

cells was comparable in the peripheral blood and the inflamed ear in the chimeras transplanted with cells from two wild type donors (WT:WT chimeras; Figs 4b-c). Importantly, the percentage of  $Syk^{-/-}$  CD45.2 cells in the inflamed ear tissue was also similar to that in the peripheral blood in WT: $Syk^{-/-}$  chimeras (Fig 4b), and the calculated relative migration of  $Syk^{-/-}$  cells was similar to, or even higher than that of wild type cells (Fig 4c;  $p = 4.4 \times 10^{-6}$ ). Those results indicate that  $Syk^{-/-}$  neutrophils are intrinsically capable of migrating to the site of inflammation, arguing against an intrinsic migration defect in  $Syk^{-/-}$  neutrophils.

Taken together, although neutrophils failed to accumulate in the ear of anti-C7 antibody-treated  $Syk^{-/-}$  bone marrow chimeras, this was not due to an intrinsic migration defect of  $Syk^{-/-}$  neutrophils since those cells were able to accumulate at the site of inflammation when wild type cells were also present in mixed bone marrow chimeras.

#### *The $Syk^{-/-}$ mutation blocks the accumulation of proinflammatory mediators in vivo*

An alternative explanation for the abrogation of neutrophil accumulation in  $Syk^{-/-}$  chimeras (Fig 4a) is that Syk deficiency may interfere with the development of a proper inflammatory (chemoattractant) microenvironment. As shown in Fig 4d, systemic administration of anti-C7 antibodies dramatically increased tissue levels of CXCL2 (MIP-2) in the ear of wild-type but not  $Syk^{-/-}$  bone marrow chimeras ( $p < 10^{-17}$ ). Similarly, hematopoietic deficiency of Syk abrogated the accumulation of the proinflammatory cytokine IL-1 $\beta$  (Fig 4e;  $p = 1.6 \times 10^{-7}$ ). Moreover, anti-C7 antibodies also moderately increased the level of the lipid mediator LTB<sub>4</sub> (a major neutrophil chemoattractant in various inflammatory conditions), in wild-type but not  $Syk^{-/-}$  bone marrow chimeras (Fig 4f;  $p = 0.038$ ).

Taken together, hematopoietic deficiency of Syk somehow prevented the accumulation of various proinflammatory agonists at the site of inflammation, likely leading to the defective accumulation of  $Syk^{-/-}$  neutrophils and subsequent protection from clinical disease.

#### *$Syk^{-/-}$ neutrophils fail to respond to type VII collagen-containing immune complexes in vitro*

Since neutrophils are capable of releasing various chemokines, cytokines and lipid mediators (Kovács et al., 2014; Tecchio et al., 2014; Németh et al., 2016), we hypothesized that the above in vivo findings may be due to defective responses of  $Syk^{-/-}$



<sup>-/-</sup> neutrophils to type VII collagen-containing immune complexes. Indeed, *Syk*<sup>-/-</sup> neutrophils failed to release superoxide (Fig 5a;  $p = 8.6 \times 10^{-4}$ ) or spread over the adhesive surface (Fig 5b) when plated on immobilized His-C7–anti-C7 immune complexes. In addition, wild-type neutrophils released large amounts of both CXCL2 and LTB<sub>4</sub>, whereas no such responses could be observed in *Syk*<sup>-/-</sup> samples (Figs 5c-d;  $p = 3.8 \times 10^{-10}$  and  $1.1 \times 10^{-16}$ , respectively). Those results suggest that Syk is indispensable for neutrophil activation by type VII collagen-containing immune complexes, explaining the defective development of an in vivo inflammatory environment in *Syk*<sup>-/-</sup> bone marrow chimeras.

## DISCUSSION

Together with an accompanying paper (Samavedam et al., submitted), here we report for the first time that the Syk tyrosine kinase is indispensable for an in vivo model of the inflammatory form of epidermolysis bullosa acquisita in experimental mice. These studies raise the possibility that Syk may be a suitable therapeutic target in that disease and, possibly, in other diseases with a similar pathogenesis.

Syk has diverse biological functions (Mócsai et al., 2010), primarily by mediating signaling from immunoreceptors such as Fc-receptors. Fc-receptors play a critical role in mouse models of bullous pemphigoid and the inflammatory form of epidermolysis bullosa acquisita (Sitaru et al., 2005; Zhao et al., 2006; Kasperkiewicz et al., 2012; Schulze et al., 2014). Together with our studies on the role of Src-family kinases (Kovács et al., 2014) and CARD9 (Németh et al., 2016), our experiments suggest that anti-C7-induced skin inflammation is mediated by Syk linking Fc receptor-mediated activation of Src-family kinases to downstream signaling through the CARD9 adapter protein. This is reminiscent of signal transduction in K/BxN serum-transfer arthritis and recognition of fungal pathogens (Gross et al., 2009).

In agreement with other studies on neutrophil function (Németh and Mócsai, 2012; Mócsai, 2013), our results suggest an important role for neutrophils in certain inflammatory autoimmune subepidermal blistering skin disease models. Our results of defective in vivo recruitment of *Syk*<sup>-/-</sup> neutrophils despite apparently normal intrinsic migratory capacity (Figs 4a-c) and the defective accumulation of neutrophil-attracting proinflammatory mediators (CXCL2 and LTB<sub>4</sub>) in vivo (Figs 4d,f) and in in vitro neutrophil assays (Figs 5c-d) suggest that the principal role of Syk is to promote feedback amplification loops through proinflammatory mediator release by neutrophils (Németh and Mócsai, 2016). Though we cannot exclude the role of Syk expression in another cell type, neutrophil-specific deletion of Syk completely protected mice from

anti-C7-induced skin pathology (T. N. and A. M., unpublished observation), indicating the central role for neutrophil-derived Syk in the disease process.

Besides identifying Syk as a critical player in autoantibody-induced skin inflammation, our results also raise a number of novel questions. What is the role of Syk in the initial, immunization phase of autoimmune bullous skin diseases, or the very first steps of anti-C7-induced skin inflammation before the initiation of the neutrophil-mediated feedback amplification process? Would it be possible to document differential chemokine gene expression of wild type and *Syk*<sup>-/-</sup> neutrophils in mixed bone marrow chimeras? Do our conclusions also apply to other autoimmune subepidermal blistering skin diseases where the autoantigen is other than type VII collagen or where the inflammatory component is less pronounced? How much can we extrapolate our findings on mouse models to human autoimmune and other inflammatory skin diseases? Those and other questions need to be addressed by future follow-up studies.

Parallel to our own study initiated by the relationship between Src-family kinases and Syk (Berton et al., 2005; Kovács et al., 2014; Futosi and Mócsai, 2016), another study described in an accompanying paper (Samavedam et al., submitted) also identified Syk as a core signaling hub in the inflammatory form of epidermolysis bullosa acquisita. While both papers conclude that Syk is critical for disease development, they also complement each other by addressing different additional aspects, such as additional signaling and mechanistic experiments in our study and bioinformatics and pharmacological aspects in the accompanying paper.

The pharmacological therapy of bullous pemphigoid and epidermolysis bullosa acquisita still relies on rather nonspecific immunosuppressive and anti-inflammatory agents. We have identified Syk as a critical component of autoantibody-induced skin inflammation in experimental mice. Though there are clear differences between our mouse model and the corresponding human disease(s) (passive vs. active immunization; neutrophils vs. eosinophils dominating the inflammatory infiltrate; respectively), we believe that our mouse studies relatively closely mimic important aspects of human pathology. Syk has emerged as a potential therapeutic target in other autoimmune inflammatory diseases such as rheumatoid arthritis, as well as in Syk-dependent hematologic malignancies (Geahlen, 2014). Though fostamatinib, the first Syk inhibitor reaching clinical development raised safety concerns likely related to its poor specificity (Anastassiadis et al., 2011; Genovese et al., 2014; Weinblatt et al., 2014; Rolf et al., 2015), there is a large effort from the pharmaceutical industry to develop novel and much more specific Syk inhibitors (Norman, 2014; Walker and Croasdell, 2016). Our results, together with those described in the accompanying

paper (Samavedam et al., submitted) suggest that such Syk-specific inhibitors may be suitable for the pharmacological control of certain inflammatory autoimmune subepidermal blistering skin diseases such as the inflammatory form of epidermolysis bullosa acquisita or, possibly, the mechanistically related bullous pemphigoid.

## MATERIALS AND METHODS

### *Animals*

Mice carrying a deleted *Syk* allele (*Syk*<sup>tm1Tyb</sup>, referred to as *Syk*<sup>-</sup>) were from Victor Tybulewicz (Turner et al., 1995) and kept in heterozygous form. Recipients carrying the CD45.1 allele on the C57BL/6 genetic background (B6.SJL-*Ptprca*<sup>a</sup> mice from the Jackson Laboratory) were lethally irradiated by 11 Gy from a <sup>137</sup>Cs source using a Gamma-Service Medical D1 irradiator and then injected intravenously with fetal liver cells from *Syk*<sup>-/-</sup> and control fetuses obtained from timed mating of *Syk*<sup>+/-</sup> carriers (Mócsai et al., 2002; Jakus et al., 2010). *Hck*<sup>tm1Hev/tm1Hev</sup> *Fgr*<sup>tm1Hev/tm1Hev</sup> *Lyn*<sup>tm1Sor/tm1Sor</sup> triple knockout mice (referred to as *Hck*<sup>-/-</sup> *Fgr*<sup>-/-</sup> *Lyn*<sup>-/-</sup> or 3x SFK KO mice) were described previously (Meng and Lowell, 1998; Kovács et al., 2014). Mice were kept in individually sterile ventilated cages (Tecniplast) in a conventional facility. All animal experiments were approved by the Animal Experimentation Review Board of the Semmelweis University.

### *Autoantibody-induced skin blistering model*

The murine model of the inflammatory form of human epidermolysis bullosa acquisita was triggered by systemic administration of antibodies against collagen type VII which triggers skin inflammation through the antibody Fc portions (Sitaru et al., 2005). Rabbits were immunized with a GST-fusion protein containing a fragment of the immunodominant NC1 domain of murine type VII collagen (GST-C7), followed by total IgG preparation (anti-C7) (Sitaru et al., 2005; Csorba et al., 2010). The reactivity of the antibody preparation was tested with a His-tagged murine type VII collagen fragment (His-C7) (Csorba et al., 2010). Normal rabbit IgG (Sigma) or PBS (Thermo Fisher) was used as control.

Twelve mg pathogenic or control IgG was injected subcutaneously under isoflurane anaesthesia on Days 0, 2, 4, 6 and 8 (60 mg total IgG/mouse). Disease onset and progression was followed by clinical assessment, while quantitative scoring was based on the specific dermatological abnormalities and the size of the affected skin area (Sitaru et al., 2005; Kovács et al., 2014; Németh et al., 2016). Serum anti-C7 levels were determined by ELISA using His-C7. For histological analysis, mice were sacrificed on Day 8 (when no open wounding had occurred), their ears were fixed in

paraformaldehyde, dehydrated, embedded in paraffin, sectioned at 9  $\mu\text{m}$  thickness and stained with hematoxylin and eosin.

#### *In vivo analysis of neutrophil accumulation*

Wild type and Syk-deficient bone marrow chimeras were injected with control or pathogenic IgG. On Day 8-10, mice were sacrificed and their ears were removed. The samples were digested with Liberase II (Roche) (Weber et al., 2015). Single cell suspensions were obtained and neutrophil numbers were determined by flow cytometry on the basis of their forward and side scatter characteristics and Ly6G-positivity (Clone 1A8, BD Biosciences).

#### *In vivo neutrophil migration*

A competitive migration assay in mixed bone marrow chimeras was used to assess in vivo migration of neutrophils (Mócsai et al., 2002; Jakus et al., 2009; Kovács et al., 2014). Wild type (C57BL/6) or *Syk*<sup>-/-</sup> bone marrow cells (carrying the CD45.2 allele) were mixed at varying ratios with bone marrow cells from congenic mice expressing CD45.1 on the C57BL/6 genetic background. The cell suspension was injected intravenously into lethally irradiated CD45.1-expressing recipient mice. After bone marrow repopulation, the chimeras were subjected to experimental epidermolysis bullosa acquisita and their ears were digested (before any open wounds occurred). The percentage of CD45.2-expressing neutrophils was analyzed by flow cytometry with staining for Ly6G and CD45.2 (Clone 104, BD Biosciences).

Relative migration of the CD45.2-positive neutrophils (relative to the CD45.1-expressing wild type cells) was calculated as described (Jakus et al., 2009).

#### *Isolation and activation of neutrophils*

Mouse neutrophils were isolated from the bone marrow by Percoll (GE Healthcare) gradient centrifugation (Mócsai et al., 2003). Neutrophil assays were performed at 37 °C in HBSS (GE Healthcare) supplemented with 20 mM HEPES, pH 7.4 or in Dulbecco's Modified Eagle's Medium (DMEM, Sigma). Cell surface molecule expression was detected by anti-Ly6G-PE (Clone 1A8), anti-CD18-Biotin (Clone C71/16), anti-CXCR2-PE (Clone #242216, R&D Systems), anti-Fc $\gamma$ RII/III (Clone 2.4G2) and anti-Fc $\gamma$ RIV-PE (Clone 9E9) antibodies. Where required, secondary staining with Streptavidin-PE or mouse anti-rat-FITC (Clone MRK-1) was performed. If not otherwise stated, the antibodies were from BD Biosciences.

Immobilized immune complex-coated surfaces were obtained by binding His-C7 at 20  $\mu\text{g}/\text{ml}$  to Nunc MaxiSorp F96 plates (Thermo Fisher) or tissue culture dishes,

blocked and then treated with anti-C7 at a 1:10 dilution, otherwise as described (Jakus et al., 2008). Human serum albumin (HSA) and anti-HSA immune complexes were generated as described (Jakus et al., 2008).

For the analysis of mediator release, neutrophils were stimulated for 1 (LTB<sub>4</sub>) or 6 (cytokines) hours, and supernatants were collected for further analysis (Kovács et al., 2014; Németh et al., 2016). Superoxide release was followed by a cytochrome c reduction test (Németh et al., 2010).

#### *Isolation of other cell types*

Platelets were isolated from peripheral blood by mild centrifugation in the presence of heparin. Mast cells were cultured from the bone marrow by murine IL-3 and stem cell factor (both from Peprotech). Macrophages were obtained by culturing bone marrow cells in the presence of recombinant murine M-CSF from a conditioned medium (Kertész et al., 2012).

#### *Analysis of inflammatory mediators*

The removed ears were either crushed under liquid nitrogen and lysed by a Triton-based buffer or were cut into small pieces and were digested. The release of mediators was tested from the ear lysates, the cell-free supernatants of digested samples or of in vitro stimulated neutrophils. The levels of CXCL2, IL-1 $\beta$  and LTB<sub>4</sub> were tested by commercial ELISA kits (R&D Systems).

#### *Biochemical studies*

For analysis of Syk phosphorylation, neutrophils were plated on immune complex-covered 6-cm tissue culture dishes, incubated for 10 min at 37 °C, and lysed on ice (adherent and nonadherent cells combined) (Kovács et al., 2014). Immunoprecipitation was performed by an anti-Syk antibody (5F5, BioLegend) followed by capturing with Protein G-Agarose (Invitrogen) (Mócsai et al., 2000; Mócsai et al., 2004; Mócsai et al., 2006; Németh et al., 2016). Whole cell lysates from the same experiments were used as controls.

Samples were run on SDS-PAGE and immunoblotted using antibodies against phosphotyrosine (Clone 4G10, Merck Millipore), Syk (N19, Santa Cruz Biotechnology) or  $\beta$ -actin (Clone AC-74, Sigma) followed by incubation with peroxidase-labeled secondary antibodies (GE Healthcare). The signal was developed using the ECL system (GE Healthcare) and exposed to X-ray films.

### *Presentation of the data and statistical analysis*

Experiments were performed the indicated number of times. Quantitative graphs and kinetic curves show mean and SEM from all independent in vitro experiments or from all individual mice from the indicated number of experiments. Statistical analyses were carried out using one- or two-way (factorial) ANOVA (with treatment and genotype being the two independent variables). Area under the curve (AUC) was used for statistical analysis in kinetic measurements. P values below 0.05 were considered statistically significant.

### **ACKNOWLEDGMENT**

We thank Edina Simon for expert technical assistance; Kinga Csorba, Levente Kiss-Pápai and Krisztina Futosi for help with experiments; Kitti Ajtay and Zoltán Jakus for the histological images; Gábor Bánhegyi for access to equipment; Clifford Lowell and Victor Tybulewicz for transgenic animals. This work was supported by the European Union's FP7 Cooperation Program (Project No. 282095 (TARKINAID) to A. M. and C. S.), the Lendület program of the Hungarian Academy of Sciences (LP2013-66/2013 to A. M.), the Deutsche Forschungsgemeinschaft (SI-1281/5-1 to C. S.) and the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (to T. N.). A. M. was a recipient of a Wellcome Trust International Senior Research Fellowship (Grant No. 087782).

### **AUTHOR CONTRIBUTIONS**

T. N. and A. M. conceived the study, designed the experiments, analyzed and interpreted the data, and wrote the manuscript. T. N. performed the majority of the experiments. O. V. and C. S. purified the anti-C7 antibodies, performed some of the experiments, and provided further experimental tools and scientific advice. A. M. supervised the project.

### **CONFLICT OF INTEREST DISCLOSURE**

The authors have no conflicting financial interests.

## REFERENCES

- Abtahian F, Guerriero A, Sebzda E, Lu MM, Zhou R, Mócsai A, et al. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. *Science* 2003;299:247-51.
- Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. *Nat Biotechnol* 2011;29:1039-45.
- Baum S, Sakka N, Artsi O, Trau H, Barzilai A. Diagnosis and classification of autoimmune blistering diseases. *Autoimmun Rev* 2014;13:482-9.
- Berton G, Mócsai A, Lowell CA. Src and Syk kinases: key regulators of phagocytic cell activation. *Trends Immunol* 2005;26:208-14.
- Chiriac MT, Roesler J, Sindrilaru A, Scharffetter-Kochanek K, Zillikens D, Sitaru C. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. *J Pathol* 2007;212:56-65.
- Csorba K, Sesarman A, Oswald E, Feldrihan V, Fritsch A, Hashimoto T, et al. Cross-reactivity of autoantibodies from patients with epidermolysis bullosa acquisita with murine collagen VII. *Cell Mol Life Sci* 2010;67:1343-51.
- Elliott ER, Van Ziffle JA, Scapini P, Sullivan BM, Locksley RM, Lowell CA. Deletion of Syk in neutrophils prevents immune complex arthritis. *J Immunol* 2011;187:4319-30.
- Futosi K, Fodor S, Mócsai A. Neutrophil cell surface receptors and their intracellular signal transduction pathways. *Int Immunopharmacol* 2013;17:638-50.
- Futosi K, Mócsai A. Tyrosine kinase signaling pathways in neutrophils. *Immunol Rev* 2016;273:121-39.
- Geahlen RL. Getting Syk: spleen tyrosine kinase as a therapeutic target. *Trends Pharmacol Sci* 2014;35:414-22.
- Genovese MC, van der Heijde DM, Keystone EC, Spindler AJ, Benhamou C, Kavanaugh A, et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor- $\alpha$  antagonist. *J Rheumatol* 2014;41:2120-8.
- Gross O, Poeck H, Bscheider M, Dostert C, Hanneschlager N, Endres S, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. *Nature* 2009;459:433-6.
- Iwata H, Bieber K, Hirose M, Ludwig RJ. Animal models to investigate pathomechanisms and evaluate novel treatments for autoimmune bullous dermatoses. *Curr Pharm Des* 2015;21:2422-39.
- Jakus Z, Németh T, Verbeek JS, Mócsai A. Critical but overlapping role of Fc $\gamma$ RIII and Fc $\gamma$ RIV in activation of murine neutrophils by immobilized immune complexes. *J Immunol* 2008;180:618-29.
- Jakus Z, Simon E, Frommhold D, Sperandio M, Mócsai A. Critical role of phospholipase C $\gamma$ 2 in integrin and Fc receptor-mediated neutrophil functions and the effector phase of autoimmune arthritis. *J Exp Med* 2009;206:577-93.
- Jakus Z, Simon E, Balázs B, Mócsai A. Genetic deficiency of Syk protects mice from autoantibody-induced arthritis. *Arthritis Rheum* 2010;62:1899-910.
- Kasperkiewicz M, Schmidt E. Current treatment of autoimmune blistering diseases. *Curr Drug Discov Technol* 2009;6:270-80.

- Kasperkiewicz M, Nimmerjahn F, Wende S, Hirose M, Iwata H, Jonkman MF, et al. Genetic identification and functional validation of FcγRIV as key molecule in autoantibody-induced tissue injury. *J Pathol* 2012;228:8-19.
- Kertész Z, Győri D, Körmendi S, Fekete T, Kis-Tóth K, Jakus Z, et al. Phospholipase Cγ2 is required for basal but not oestrogen deficiency-induced bone resorption. *Eur J Clin Invest* 2012;42:49-60.
- Kim JH, Kim SC. Epidermolysis bullosa acquisita. *J Eur Acad Dermatol Venereol* 2013;27:1204-13.
- Kovács M, Németh T, Jakus Z, Sitaru C, Simon E, Futosi K, et al. The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment. *J Exp Med* 2014;211:1993-2011.
- Kulkarni S, Sitaru C, Jakus Z, Anderson KE, Damoulakis G, Davidson K, et al. PI3Kβ plays a critical role in neutrophil activation by immune complexes. *Sci Signal* 2011;4:ra23.
- Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, et al. The role of complement in experimental bullous pemphigoid. *J Clin Invest* 1995;95:1539-44.
- Liu Z, Giudice GJ, Zhou X, Swartz SJ, Troy JL, Fairley JA, et al. A major role for neutrophils in experimental bullous pemphigoid. *J Clin Invest* 1997;100:1256-63.
- Ludwig RJ, Zillikens D. Pathogenesis of epidermolysis bullosa acquisita. *Dermatol Clin* 2011;29:493-501, xi.
- Ludwig RJ. Model systems duplicating epidermolysis bullosa acquisita: a methodological review. *Autoimmunity* 2012;45:102-10.
- Meng F, Lowell CA. A β1 integrin signaling pathway involving Src-family kinases, Cbl and PI-3 kinase is required for macrophage spreading and migration. *EMBO J* 1998;17:4391-403.
- Mihai S, Chiriac MT, Takahashi K, Thurman JM, Holers VM, Zillikens D, et al. The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. *J Immunol* 2007;178:6514-21.
- Mócsai A, Jakus Z, Vántus T, Berton G, Lowell CA, Ligeti E. Kinase pathways in chemoattractant-induced degranulation of neutrophils: The role of p38 mitogen-activated protein kinase activated by Src family kinases. *J Immunol* 2000;164:4321-31.
- Mócsai A, Zhou M, Meng F, Tybulewicz VL, Lowell CA. Syk is required for integrin signaling in neutrophils. *Immunity* 2002;16:547-58.
- Mócsai A, Zhang H, Jakus Z, Kitaura J, Kawakami T, Lowell CA. G-protein-coupled receptor signaling in Syk-deficient neutrophils and mast cells. *Blood* 2003;101:4155-63.
- Mócsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, Spusta SC, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase. *Proc Natl Acad Sci USA* 2004;101:6158-63.
- Mócsai A, Abram CL, Jakus Z, Hu Y, Lanier LL, Lowell CA. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. *Nat Immunol* 2006;7:1326-33.
- Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. *Nat Rev Immunol* 2010;10:387-402.



- Mócsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. *J Exp Med* 2013;210:1283-99.
- Németh T, Futosi K, Hably C, Brouns MR, Jakob SM, Kovács M, et al. Neutrophil functions and autoimmune arthritis in the absence of p190RhoGAP: Generation and analysis of a novel null mutation in mice. *J Immunol* 2010;185:3064-75.
- Németh T, Mócsai A. The role of neutrophils in autoimmune diseases. *Immunol Lett* 2012;143:9-19.
- Németh T, Futosi K, Sitaru C, Ruland J, Mócsai A. Neutrophil-specific deletion of the CARD9 gene expression regulator suppresses autoantibody-induced inflammation in vivo. *Nat Commun* 2016;7:11004.
- Németh T, Mócsai A. Feedback amplification of neutrophil function. *Trends Immunol* 2016;37:412-24.
- Norman P. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013. *Expert Opin Ther Pat* 2014;24:573-95.
- Rolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, et al. In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. *Pharmacol Res Perspect* 2015;3:e00175.
- Samavedam UK, Mitschker N, Kasprick A, Bieber K, Schmidt E, Laskay T, et al. Whole-genome expression profiling in skin reveals SYK as a key regulator of inflammation in epidermolysis bullosa acquisita. (submitted to *J Invest Dermatol*) submitted.
- Schmidt E, Zillikens D. Pemphigoid diseases. *Lancet* 2013;381:320-32.
- Schulze FS, Beckmann T, Nimmerjahn F, Ishiko A, Collin M, Kohl J, et al. Fcγ receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. *Am J Pathol* 2014;184:2185-96.
- Sitaru C, Kromminga A, Hashimoto T, Brocker EB, Zillikens D. Autoantibodies to type VII collagen mediate Fcγ-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. *Am J Pathol* 2002;161:301-11.
- Sitaru C, Mihai S, Otto C, Chiriac MT, Hausser I, Dotterweich B, et al. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. *J Clin Invest* 2005;115:870-8.
- Sitaru C. Experimental models of epidermolysis bullosa acquisita. *Exp Dermatol* 2007;16:520-31.
- Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression. *Front Immunol* 2014;5:508.
- Turcan I, Jonkman MF. Blistering disease: insight from the hemidesmosome and other components of the dermal-epidermal junction. *Cell Tissue Res* 2015;360:545-69.
- Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. *Nature* 1995;378:298-302.
- Walker G, Croasdell G. The European League Against Rheumatism (EULAR) - 17th Annual European Congress of Rheumatology (June 8-11, 2016 - London, UK). *Drugs Today (Barc)* 2016;52:355-60.
- Weber FC, Németh T, Csepregi JZ, Dudeck A, Roers A, Ozsvári B, et al. Neutrophils are required for both the sensitization and elicitation phase of contact hypersensitivity. *J Exp Med* 2015;212:15-22.

- Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. *N Engl J Med* 2010;363:1303-12.
- Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheumatol* 2014;66:3255-64.
- Zhao M, Trimbeger ME, Li N, Diaz LA, Shapiro SD, Liu Z. Role of FcRs in animal model of autoimmune bullous pemphigoid. *J Immunol* 2006;177:3398-405.

## FIGURE LEGENDS

### Figure 1

*Type VII collagen-containing immune complexes trigger neutrophil activation and Syk phosphorylation through Src-family kinases*

(a) Respiratory burst of wild-type (WT) mouse neutrophils plated on surfaces treated with His-C7 and/or anti-C7. (b) His-C7–anti-C7 immune complexes trigger spreading of wild-type neutrophils. (c) Specificity of the His-C7–anti-C7- and HSA–anti-HSA-induced responses. (d-e) Src-family kinases are essential for His-C7–anti-C7 immune complex-triggered superoxide release and Syk-phosphorylation. Kinetic curves and graphs in a, c and d show mean and SEM of 2-3 independent experiments. In Panels a and d, control data points were subtracted. Panels b and e are representative of 2-3 independent experiments. See the text for actual p values. C7, type VII collagen fragment; HSA, human serum albumin; 3x SFK KO, *Hck<sup>-/-</sup>Fgr<sup>-/-</sup>Lyn<sup>-/-</sup>*.

### Figure 2

*Characterization of wild-type and Syk<sup>-/-</sup> bone marrow chimeras and their neutrophils*

(a) Flow cytometric analysis of the donor-specific CD45.2 epitope in peripheral blood neutrophils tested 4 weeks after bone marrow (BM) transplantation. (b) Immunoblot analysis of Syk expression in various cell types from wild-type (WT) and *Syk<sup>-/-</sup>* bone marrow chimeras. (c) Circulating neutrophil (PMN) counts in wild-type and *Syk<sup>-/-</sup>* chimeras. (d) Average neutrophil number isolated from the bone marrow of the different chimeras. (e) Cell surface molecule expression of wild-type and *Syk<sup>-/-</sup>* bone marrow-isolated neutrophils. Panels a, b and e are representative of 3-10 independent experiments. Graphs in Panel c and d show mean and SEM from 9-11 mice. See the text for actual p values.

### Figure 3

*Syk is required for experimental epidermolysis bullosa acquisita*

Skin disease was triggered in wild-type (WT) or *Syk<sup>-/-</sup>* bone marrow chimeras by anti-C7 antibodies and was followed by photographing the heads, the trunks and the ears (a), clinical assessment of the body surface affected (b) and the overall disease severity (c). (d) Serum anti-C7 levels were tested by ELISA. (e) Hematoxylin and eosin stained ear histological sections are presented from WT and *Syk<sup>-/-</sup>* chimeras. The right images were magnified from the pictures seen on the left (10x original magnification). Representative images (a, e) or mean and SEM (b-c) from 3 control and 12-13 anti-C7-treated mice per genotype from 3 independent experiments are shown. Panel d shows mean and SEM from 2-3 control and 9-11 anti-C7-treated mice from 2 independent experiments. See the text for actual p values.

### Figure 4

*Syk is essential for forming the inflammatory environment*

(a) The accumulation of neutrophils in the ear upon anti-C7 injection was determined by flow cytometry. (b-c) Mixed bone marrow chimeras with CD45.1-expressing wild type (WT) and

CD45.2-expressing WT or *Syk*<sup>-/-</sup> hematopoietic cells were injected with anti-C7 antibodies and neutrophil accumulation was determined by flow cytometric analysis. In Panel b, each dot represents an individual ear, while Panel c shows the relative migration of WT and *Syk*<sup>-/-</sup> neutrophils. (d-f) Decreased in vivo CXCL2, IL-1 $\beta$  and LTB<sub>4</sub> levels in the ears of *Syk*-deficient chimeras. Graphs represent mean and SEM from 3-5 (a) or 2-6 mice (c), 3-4 control or 5-7 anti-C7-treated mice (d-f) per group from 2-3 independent experiments. See the text for actual p values.

### **Figure 5**


*Syk is required for neutrophil responses on immobilized His-C7-anti-C7 immune complexes*


Respiratory burst (a), cell spreading (b), CXCL2 (c) and LTB<sub>4</sub> release (d) of wild-type (WT) and *Syk*<sup>-/-</sup> neutrophils. Curves in Panel a show mean and SEM of 3 independent experiments; control data points were subtracted. Panel b is representative of 3 independent experiments. Graphs in (c-d) show mean and SEM from 3 independent experiments. See the text for actual p values.






### **Supplementary Figure 1**


*Western blot images with more details*

Western blot images showing Syk phosphorylation and Syk expression in *Syk*-immunoprecipitated samples and whole cell lysates of neutrophils from Fig 1e. IP, immunoprecipitation; 3x SFK KO, *Hck*<sup>-/-</sup>*Fgr*<sup>-/-</sup>*Lyn*<sup>-/-</sup>; WB, Western blot; WCL, whole cell lysate; WT, wild-type















# Németh et al. - Figure 5



# Németh et al. - Suppl. Figure 1

